R&D

We contribute to promoting human health.
We are the global leader in stem cell therapies

  • HOME
  • R&D
  • Stem cell treatment
  • Screening
    material
  • Preclinical
  • Clinical Phase 1
  • Clinical Phase 2
  • Clinical Phase 3
Adipose-derived Stem cell

Atopic dermatitis therapeutics (ADSTEM)

Parkinson's disease therapeutics (PDSTEM)

Rheumatoid arthritis therapeutics (RASTEM)

 
 
 
 
Urine-derived
Stem cell

Chronic renal failure therapeutics (KDSTEM)

 
 
 
 

Stem cell therapy

  • ADSTEM inj.

    ADSTEM Inj. Is an autologous adipose-derived mesenchymal stem cell therapy drug that is being developed for patients with moderate to severe subacute and chronic atopic dermatitis. The first phase of ADSTEM Inj.’s clinical trials has been completed and the second phase of clinical trials is currently being conducted at five hospitals including Chung-Ang University Hospital.

    Product name : ADSTEM Inj.

    Manufacturer : EHL Bio Co.,Ltd

    Target efficacy effect : Treatment of moderate to severe subacute and chronic atopic dermatitis

    Method of injection : Intravenous injection, repeated administration twice

  • RASTEM inj.

    RASTEM Inj. Is an autologous adipose-derived mesenchymal stem cell therapy drug that is being developed for patients with moderate or more rheumatoid arthritis. RASTEM Inj. Is currently completing a non-clinical study and is preparing for a clinical trial.

    Product name : RASTEM Inj.

    Manufacturer : EHL Bio Co.,Ltd

    Target efficacy effect : Treatment of moderate or more rheumatoid arthritis

    Method of injection : Intravenous injection, repeated administration

  • PDSTEM inj.

    PDSTEM Inj. Is an autologous adipose-derived mesenchymal stem cell treatment and is being developed for patients with Parkinson's disease. PDSTEM Inj. Is currently in non-clinical progress.

    Product name : PDSTEM Inj.

    Manufacturer : EHL Bio Co.,Ltd

    Target efficacy effect : Treatment of Parkinson's disease.

    Method of injection : Intravenous injection, repeated administration

  • KDSTEM inj.

    KDSTEM Inj. Is a treatment for autologous urine-derived mesenchymal stem cells and is being developed for patients with chronic renal failure. Urine-derived stem cells express Klotho. Klotho is known as a representative "anti-aging protein" because it plays a role in antioxidant, cell aging suppression, angiogenesis, and human metabolism regulation. KDSTEM Inj. Is currently undergoing non-clinical studies.

    Product name : KDSTEM Inj.

    Manufacturer : EHL Bio Co.,Ltd

    Target efficacy effect : Treatment of chronic renal failure

    Method of injection : Intravenous injection, repeated administration